Obsessive compulsive symptoms in schizophrenia:

Obsessive‒compulsive symptoms and associated factors among people with schizophrenia attending services at referral hospitals in Eastern Ethiopia

BACKGROUND

Obsessive-compulsive symptoms are mental health conditions marked by the presence of obsessions and/or compulsions. Even though significant portion people with schizophrenia are reportedly affected by obsessive-compulsive symptoms, there is scarce of information related to this topic in Africa, and particularly in study area.

OBJECTIVE

This study aimed to assess the magnitude and associated factors of obsessive‒compulsive symptoms among people with schizophrenia attending services at referral hospitals in Eastern Ethiopia from February 15 to March 15, 2024.

METHODS

An institutional-based, cross-sectional study was conducted among adults with schizophrenia. Systematic sampling was used to select 422 study participants. The Yale-Brown Obsessive-Compulsive Scale was used to assess obsessive-compulsive symptoms. Data entry and analysis were performed by EpiData 4.6 and STATA 14, respectively. Bivariable and multivariable logistic regression were performed, and variables with p values < 0.05 were considered statistically significant.

RESULTS

The proportion with obsessive‒compulsive symptoms in this study was 44.07% (95% CI, 39.33%-48.92%). After adjusting for possible confounders, duration of schizophrenia from 3-4 years (AOR = 3.41; 95% CI, 1.28-9.05), duration of schizophrenia 5 years and above (AOR = 6.08; 95% CI, 2.26-16.31), current use of alcohol (AOR = 2.12; 95% CI, 1.09-4.12), current use of khat (AOR = 6.09; 95% CI, 3.15-11.74), being a probable case of anxiety (AOR = 3.57; 95% CI, 1.95-6.53), being a probable case of depression (AOR = 4.56; 95% CI, 2.39-8.66), being on Risperidone (AOR = 5.08; 95% CI, 2.52-10.23) and being on Olanzapine (AOR = 5.95; 95% CI, 2.72-13.04) were significantly associated with obsessive‒compulsive symptoms. CONCLUSIONS AND RECOMMENDATION: The prevalence of obsessive‒compulsive symptoms was relatively high. Timely detection and appropriate interventions are crucial and special consideration is better to be given for those with comorbid substance use, comorbid anxiety and depression, as well as those taking second-generation antipsychotics.

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis

The comorbidity of obsessive–compulsive symptoms (OCS) in the context of schizophrenia is often not recognised by clinicians, and patients may not report these symptoms until they become severe. However, there is a reported prevalence of 10–24% for obsessive–compulsive disorder (OCD) in schizophrenia and related disorders. The onset of OCS/OCD has been noted to occur both before and after the diagnosis of schizophrenia or schizoaffective disorder. It has also been known to occur following commencement of treatment with antipsychotic medications, especially clozapine. Current literature provides limited guidance for treatment. Review of the current evidence supports: addition of selective serotonin reuptake inhibitors (SSRIs) to antipsychotics; addition of aripiprazole, amisulpride or lamotrigine; or reduction in the dosage of clozapine. There is also evidence supporting the addition of cognitive–behavioural therapy and electroconvulsive therapy (ECT). The SSRIs that are evidenced to be useful are fluvoxamine, escitalopram, sertraline and paroxetine. More studies are needed to expand the evidence base. Early targeted interventions are recommended.